Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease

NCT ID: NCT01374880

Last Updated: 2013-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-06-30

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this work is to investigate and then to sequence new biomarkers in the plasma of patients presenting with dyspnea secondary or not to heart failure, and study their diagnostic and prognostic value.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Plasma samples for patients with dyspnea, edema, with or without heart failure; ambulatory or admitted for cardiac decompensation (even with cardiac shock and LVAD) ; or entering a cardiac rehabilitation program, will be prospectively collected.

The objective of this work is to investigate and then to sequence new proteins in the plasma of these patients for diagnostic and prognostic purpose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Dyspnea Pulmonary Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Heart failure Dyspnea Heart disease Pulmonary disease Natriuretic peptide Rehabilitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dyspnea cohort

Dyspnea cohort

No interventions assigned to this group

Stable chronic heart failure

Stable chronic heart failure

No interventions assigned to this group

Valvular heart disease

Valvular heart disease

No interventions assigned to this group

Ventricular assist device

Ventricular assist device

No interventions assigned to this group

Cardiac arrest

Cardiac arrest

No interventions assigned to this group

Cardiac rehabilitation

Cardiac rehabilitation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients presenting with shortness of breath secondary or not to heart failure, even with cardiac shock and LVAD.
* Patients with valvular disease
* chronic stable heart failure.
* post- partum Cardiomyopathy

Exclusion Criteria

* terminal cancer
* progressive neurological disease
* pregnancy
* opposition of the patient
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role collaborator

University Paris 7 - Denis Diderot

OTHER

Sponsor Role collaborator

ThermoFisher Scientific Brahms Biomarkers France

INDUSTRY

Sponsor Role collaborator

Hoffmann-La Roche

INDUSTRY

Sponsor Role collaborator

Alere San Diego

INDUSTRY

Sponsor Role collaborator

Servier

INDUSTRY

Sponsor Role collaborator

Helsinki University Central Hospital

OTHER

Sponsor Role collaborator

University Hospital, Basel, Switzerland

OTHER

Sponsor Role collaborator

Massachusetts General Hospital

OTHER

Sponsor Role collaborator

The Cleveland Clinic

OTHER

Sponsor Role collaborator

Maastricht University Medical Center

OTHER

Sponsor Role collaborator

Department of Laboratory Medicine, Konventhospital Barmherzige Brueder, Linz, Austria

UNKNOWN

Sponsor Role collaborator

Hospital Universitario Virgen de la Arrixaca

OTHER

Sponsor Role collaborator

University Hospital Monastir, Tunis

OTHER

Sponsor Role collaborator

Università degli Studi di Brescia

OTHER

Sponsor Role collaborator

Intensive and Cardiac Care Unit, Nippon Medical School, Tokyo, Japan

UNKNOWN

Sponsor Role collaborator

Brno University Hospital

OTHER

Sponsor Role collaborator

University of Cape Town

OTHER

Sponsor Role collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alain Cohen-Solal, PHD

Role: STUDY_DIRECTOR

Institut National de la Santé Et de la Recherche Médicale, France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lariboisiere hospital

Paris, Île-de-France Region, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alexandre Mebazaa, PHD

Role: CONTACT

Phone: +33(0)149958071

Email: [email protected]

Alain Cohen-Solal, PHD

Role: CONTACT

Phone: +33(0)149956608

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Said Laribi, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Badoz M, Arrigo M, Mogenet AC, Sadoune M, Meneveau N, Mebazaa A, Seronde MF. Assessment of successful percutaneous mitral commissurotomy by MRproANP and sCD146. BMC Cardiovasc Disord. 2020 Apr 5;20(1):157. doi: 10.1186/s12872-020-01435-y.

Reference Type DERIVED
PMID: 32248819 (View on PubMed)

Van Aelst LNL, Abraham M, Sadoune M, Lefebvre T, Manivet P, Logeart D, Launay JM, Karim Z, Puy H, Cohen-Solal A. Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up. Eur J Heart Fail. 2017 Aug;19(8):1075-1076. doi: 10.1002/ejhf.837. Epub 2017 May 17. No abstract available.

Reference Type DERIVED
PMID: 28516737 (View on PubMed)

Vodovar N, Seronde MF, Laribi S, Gayat E, Lassus J, Boukef R, Nouira S, Manivet P, Samuel JL, Logeart D, Ishihara S, Cohen Solal A, Januzzi JL Jr, Richards AM, Launay JM, Mebazaa A; GREAT Network. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J. 2014 Dec 21;35(48):3434-41. doi: 10.1093/eurheartj/ehu314. Epub 2014 Aug 24.

Reference Type DERIVED
PMID: 25157115 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Unité 942 INSERM

Identifier Type: OTHER

Identifier Source: secondary_id

CNIL number: 910198

Identifier Type: -

Identifier Source: org_study_id